论文部分内容阅读
本文探讨围手术期胰腺癌患者细胞免疫功能的水平和胸腺肽α1治疗对机体细胞免疫功能的影响。采用直接免疫荧光技术和流式细胞仪测定T淋巴细胞亚群 (CD3+ 、CD4+ 、CD8+ )和NK细胞的百分率 ,并动态观察胰腺癌患者介入治疗前后和手术前后 ,以及围手术期使用胸腺肽α1后上述百分率和比值的变化。结果显示 ,胰腺癌患者外周血CD3+ 、CD4+ 百分率和CD4+ /CD8+ 比值明显低下 ,介入治疗 1周后下降更显著 ,但在介入治疗 3～ 4周有所恢复 ,手术后再次出现下降 ;NK细胞比率变化则无显著差别。使用胸腺肽α1可明显提高介入治疗和手术后上述细胞的百分率和CD4+ /CD8+ 比值。表明胰腺癌患者的细胞免疫功能表达低下 ,介入化疗和手术创伤可降低抑制机体的细胞免疫功能 ;胸腺肽α1能增强患者围手术期的细胞免疫功能。
This article discusses the level of cellular immune function in patients with perioperative pancreatic cancer and the effect of thymosin α1 treatment on cellular immune function in the body. The percentages of T-lymphocyte subsets (CD3+, CD4+, CD8+) and NK cells were measured by direct immunofluorescence and flow cytometry, and were dynamically observed before and after the interventional treatment of pancreatic cancer patients, and after perioperative use of thymosin α1. The above percentage and ratio changes. The results showed that the percentages of CD3+, CD4+, and CD4+/CD8+ in peripheral blood were significantly lower in patients with pancreatic cancer. The ratio of CD4+/CD8+ in peripheral blood was significantly lower in patients with pancreatic cancer. The decline was more significant after 1 week of interventional therapy, but it recovered after 3 to 4 weeks of interventional therapy and decreased again after surgery. NK cell ratio There is no significant difference in changes. The use of thymosin alpha 1 can significantly increase the percentage of cells and CD4+/CD8+ ratios of the aforementioned cells after interventional therapy and surgery. It indicates that the expression of cellular immune function is low in patients with pancreatic cancer. Interventional chemotherapy and surgical trauma can reduce the cellular immune function; thymosin α1 can enhance the perioperative cellular immune function.